RE: Highlights from the zoom ....27 Jun 2024 13:51
MrJinx ... I am assuming if the 1st patient shows efficacy, this will rerate really hard and if not, we go onto the 2nd and same again. If all 3 are positive, this could be well over 10p+ and looking at phase 2 when pharma will arrive and a placing would not be needed and they could get money from these companies. Worst case no pharma arrives and they can happily place at 6p or 8p etc. This should have been the case post FDA approval but sadly the shorters knew funding was challenging and destroyed sentiment.
This is not for the risk adverse but 2024 is the year that Hemo will go ballistic or not I feel. For all those that sold out, if you want to be part of the hemo story, this is an absolute bargain at 1.25p and you may never get a chance like this again. Of course those that don't like risk or cannot wait, just watch by the sidelines !!!